Completed
To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia
NCT00426816
- Conditions
- Dyssomnias, Mental Disorders, Nervous System Diseases, +3 more
- Locations
-
- GSK Investigational Site Mannheim, Baden-Wurttemberg, Germany
- GSK Investigational Site Cottbus, Brandenburg, Germany
- GSK Investigational Site Hamburg, Free and Hanseatic City of Hamburg, Germany
- GSK Investigational Site Schwerin, Mecklenburg-Vorpommern, Germany